Patient selection? One fits all (monotherapy versus combined therapy)?

S. Herkenrath (Köln, Germany)

Source: Sleep and Breathing Conference 2021

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Herkenrath (Köln, Germany). Patient selection? One fits all (monotherapy versus combined therapy)?. Sleep and Breathing Conference 2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference?
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006

Second line chemotherapy with cisplatin (C) plus paclitaxel (P) for chemo refractory and resistant SCLC patients (pts). Did it change the overall disease’s prognosis?
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003

Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001

Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020

Difference of patient background with pneumonia between monotherapy and combination
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

Using remote directly observed therapy (R-DOT) for optimising asthma therapy.
Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma
Year: 2017

Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021

Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study
Source: International Congress 2017 – Clinical challenges in chronic lung diseases
Year: 2017

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
Source: ERJ Open Res, 5 (1) 00185-2018; 10.1183/23120541.00185-2018
Year: 2019

Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011

Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021

Which method is effective in patient with asthma to guide the treatment? (2 year follow-up study)
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE)
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005

Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015

Long-term oral antibiotic treatment: why, what, when and to whom?
Source: Eur Respir Monogr 2017; 75: 185-205
Year: 2017

Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study
Source: Eur Respir J 2003; 22: Suppl. 45, 527s
Year: 2003